{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Immunological responses", "Inflammation", "Inflammatory bowel diseases", "Pro-inflammatory", "Transmembrane serine protease 2"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35046622", "DateCompleted": {"Year": "2022", "Month": "01", "Day": "21"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "08"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.3748/wjg.v27.i46.7943"], "Journal": {"ISSN": "2219-2840", "JournalIssue": {"Volume": "27", "Issue": "46", "PubDate": {"Year": "2021", "Month": "Dec", "Day": "14"}}, "Title": "World journal of gastroenterology", "ISOAbbreviation": "World J Gastroenterol"}, "ArticleTitle": "Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment.", "Pagination": {"StartPage": "7943", "EndPage": "7955", "MedlinePgn": "7943-7955"}, "Abstract": {"AbstractText": ["Inflammatory bowel diseases (IBD) refer to a subgroup of chronic, progressive, long-term, and relapsing inflammatory disorders. IBD may spontaneously grow in the colon, and in severe cases may result in tumor lesions such as invasive carcinoma in inflamed regions of the intestine. Recent epidemiological reports indicate that old age and underlying diseases such as IBD contribute to severity and mortality in patients with coronavirus disease 2019 (COVID-19). Currently, the ongoing COVID-19 pandemic caused serious morbidity and mortality worldwide. It has also been shown that the transmembrane serine protease 2 is an essential factor for viral activation and viral engulfment. Generally, viral entry causes a 'cytokine storm' that induces excessive generation of proinflammatory cytokines/chemokines including interleukin (IL)-6, IL-2, IL-7, tumor necrosis factor-\u03b1, and interferon-\u03b3. Future research could concentrate on developing inflammatory immunological responses that are efficient to encounter COVID-19. Current analysis elucidates the role of inflammation and immune responses during IBD infection with COVID-19 and provides a list of possible targets for IBD-regulated therapies in particular. Data from clinical, <i>in vitro</i>, and <i>in vivo</i> studies were collected in English from PubMed, Google Scholar, Scopus, and the Cochrane library until May 2021."], "CopyrightInformation": "\u00a9The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Lashgari", "ForeName": "Naser-Aldin", "Initials": "NA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Momeni Roudsari", "ForeName": "Nazanin", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 141554364, Iran."}], "LastName": "Momtaz", "ForeName": "Saeideh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "World J Gastroenterol", "NlmUniqueID": "100883448", "ISSNLinking": "1007-9327"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Serine Proteases"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "Angiotensin-Converting Enzyme 2"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Angiotensin-Converting Enzyme 2"}, {"QualifierName": [], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapy"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": [], "DescriptorName": "Neoplasm Recurrence, Local"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Serine Proteases"}], "CoiStatement": "Conflict-of-interest statement: The authors have no conflicts of interest to disclose."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020;10:779\u2013782.", "ArticleIdList": ["PMC7437472", "32276929"]}, {"Citation": "Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020;8:775\u2013781.", "ArticleIdList": ["PMC7435006", "32438878"]}, {"Citation": "Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020;323:2329\u20132330.", "ArticleIdList": ["32329799"]}, {"Citation": "Li X, Ma X. Acute respiratory failure in COVID-19: is it \"typical\" ARDS? Crit Care. 2020;24:198.", "ArticleIdList": ["PMC7202792", "32375845"]}, {"Citation": "Lashgari NA, Roudsari NM, Momtaz S, Ghanaatian N, Kohansal P, Farzaei MH, Afshari K, Sahebkar A, Abdolghaffari AH. Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases. Curr Med Chem. 2021;28:1605\u20131624.", "ArticleIdList": ["32364064"]}, {"Citation": "Lashgari NA, Roudsari NM, Zandi N, Pazoki B, Rezaei A, Hashemi M, Momtaz S, Rahimi R, Shayan M, Dehpour AR, Abdolghaffari AH. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Mol Biol Rep. 2021;48:855\u2013874.", "ArticleIdList": ["33394234"]}, {"Citation": "Neurath MF. COVID-19 and immunomodulation in IBD. Gut. 2020;69:1335\u20131342.", "ArticleIdList": ["PMC7211083", "32303609"]}, {"Citation": "Reinsch S, Stallmach A, Grunert PC. The COVID-19 Pandemic: Fears and Overprotection in Pediatric Patients with Inflammatory Bowel Disease and Their Families. Pediatr Gastroenterol Hepatol Nutr. 2021;24:65\u201374.", "ArticleIdList": ["PMC7813565", "33505895"]}, {"Citation": "Yang C, Xiao SY. COVID-19 and inflammatory bowel disease: A pathophysiological assessment. Biomed Pharmacother. 2021;135:111233.", "ArticleIdList": ["PMC7834878", "33433350"]}, {"Citation": "Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, van der Voort PH, Mulder DJ, van Goor H. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) J Pathol. 2020;251:228\u2013248.", "ArticleIdList": ["PMC7276767", "32418199"]}, {"Citation": "Su\u00e1rez-Fari\u00f1as M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro RC, Di'Narzo A, Martinez-Delgado G, Suprun M, Corley MJ, Stojmirovic A, Houten SM, Peters L, Curran M, Brodmerkel C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Ndhlovu L, Cerf-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. Gastroenterology. 2021;160:287\u2013301.e20.", "ArticleIdList": ["PMC7516468", "32980345"]}, {"Citation": "Batchu SN, Kaur H, Yerra VG, Advani SL, Kabir MG, Liu Y, Klein T, Advani A. Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19. Diabetes. 2021;70:759\u2013771.", "ArticleIdList": ["33310740"]}, {"Citation": "Sakamoto A, Kawakami R, Kawai K, Gianatti A, Pellegrini D, Kutys R, Guo L, Mori M, Cornelissen A, Sato Y, Bellasi A, Faggi L, Hong C, Romero M, Guagliumi G, Virmani R, Finn AV. ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. Arterioscler Thromb Vasc Biol. 2021;41:542\u2013544.", "ArticleIdList": ["33086866"]}, {"Citation": "Kermani NZ, Song WJ, Badi Y, Versi A, Guo Y, Sun K, Bhavsar P, Howarth P, Dahlen SE, Sterk PJ, Djukanovic R, Adcock IM, Chung KF U-BIOPRED Consortium. Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma. Respir Res. 2021;22:10.", "ArticleIdList": ["PMC7788167", "33413387"]}, {"Citation": "Wang H, Sun X, VonCannon JL, Kon ND, Ferrario CM, Groban L. Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19. Hypertens Res 2021; 1-3.", "ArticleIdList": ["PMC7856449", "33536584"]}, {"Citation": "Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein. Biochimie. 2021;180:143\u2013148.", "ArticleIdList": ["PMC7834737", "33181224"]}, {"Citation": "Zarubin A, Stepanov V, Markov A, Kolesnikov N, Marusin A, Khitrinskaya I, Swarovskaya M, Litvinov S, Ekomasova N, Dzhaubermezov M, Maksimova N, Sukhomyasova A, Shtygasheva O, Khusnutdinova E, Radzhabov M, Kharkov V. Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy. Genes (Basel) 2020;12", "ArticleIdList": ["PMC7823984", "33375616"]}, {"Citation": "Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, Miyoshi K, Kishigami S, Ueno T, Iwatani Y, Suzuki T, Tokunaga K. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun. 2021;12:848.", "ArticleIdList": ["PMC7870668", "33558493"]}, {"Citation": "Beyerstedt S, Casaro EB, Rangel \u00c9B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 2021; 1-15.", "ArticleIdList": ["PMC7778857", "33389262"]}, {"Citation": "Toyonaga T, Araba KC, Kennedy MM, Keith BP, Wolber EA, Beasley C, Steinbach EC, Schaner MR, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Kapadia MR, Guillem JG, Gulati AS, Sethupathy P, Furey TS, Ehre C, Sheikh SZ. Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Sci Rep. 2021;11:13533.", "ArticleIdList": ["PMC8241995", "34188154"]}, {"Citation": "Kyrou I, Randeva HS, Spandidos DA, Karteris E. Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19. Signal Transduct Target Ther. 2021;6:21.", "ArticleIdList": ["PMC7812344", "33462185"]}, {"Citation": "Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY) 2020;12:10087\u201310098.", "ArticleIdList": ["PMC7346072", "32501810"]}, {"Citation": "Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, Xin Y, Zhuang L. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother. 2020;131:110678.", "ArticleIdList": ["PMC7444942", "32861070"]}, {"Citation": "Xiao L, Sakagami H, Miwa N. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? Viruses. 2020;12", "ArticleIdList": ["PMC7290508", "32354022"]}, {"Citation": "Nowak JK, Lindstr\u00f8m JC, Kalla R, Ricanek P, Halfvarson J, Satsangi J. Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease. Gastroenterology. 2020;159:1151\u20131154.e2.", "ArticleIdList": ["PMC7217073", "32413354"]}, {"Citation": "de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azev\u00eado Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14:597\u2013600.", "ArticleIdList": ["PMC7215143", "32417709"]}, {"Citation": "Rothan HA, Byrareddy SN. The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Pediatr Allergy Immunol. 2021;32:17\u201322.", "ArticleIdList": ["PMC7887110", "32897642"]}, {"Citation": "Zipeto D, Palmeira JDF, Arga\u00f1araz GA, Arga\u00f1araz ER. ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. Front Immunol. 2020;11:576745.", "ArticleIdList": ["PMC7575774", "33117379"]}, {"Citation": "Abassi Z, Higazi AAR, Kinaneh S, Armaly Z, Skorecki K, Heyman SN. ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. Front Physiol. 2020;11:574753.", "ArticleIdList": ["PMC7573220", "33123031"]}, {"Citation": "Burgue\u00f1o JF, Reich A, Hazime H, Quintero MA, Fernandez I, Fritsch J, Santander AM, Brito N, Damas OM, Deshpande A, Kerman DH, Zhang L, Gao Z, Ban Y, Wang L, Pignac-Kobinger J, Abreu MT. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Inflamm Bowel Dis. 2020;26:797\u2013808.", "ArticleIdList": ["PMC7188157", "32333601"]}, {"Citation": "Potdar AA, Dube S, Naito T, Botwin G, Haritunians T, Li D, Yang S, Bilsborough J, Denson LA, Daly M, Targan SR, Fleshner P, Braun J, Kugathasan S, Stappenbeck TS, McGovern DPB. Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease. medRxiv. 2020"}, {"Citation": "Azimi A. TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19. 2020."}, {"Citation": "Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Dami\u00e3o AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909.", "ArticleIdList": ["PMC7153358", "32321117"]}, {"Citation": "Fragoso RP, Rodrigues M. COVID-19 and pediatric inflammatory bowel disease: How to manage it? Clinics (Sao Paulo) 2020;75:e1962.", "ArticleIdList": ["PMC7249989", "32520223"]}, {"Citation": "Al-Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae F. Prevention, diagnosis and management of COVID-19 in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2020.", "ArticleIdList": ["PMC7267115", "32348598"]}, {"Citation": "An P, Ji M, Ren H, Su J, Ding NS, Kang J, Yin A, Zhou Q, Shen L, Zhao L, Jiang X, Xiao Y, Tan W, Lv X, Li J, Liu S, Zhou J, Chen H, Xu Y, Liu J, Chen M, Cao J, Zhou Z, Tan S, Yu H, Dong W, Ding Y. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. Lancet Gastroenterol Hepatol. 2020;5:525\u2013527.", "ArticleIdList": ["PMC7164865", "32311321"]}, {"Citation": "Prentice RE, Tjandra D, Garg M, Lubel JS, Fourlanos S, Johnson D, Al-Ani A, Christensen B. Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. Aliment Pharmacol Ther. 2020;52:1422\u20131423.", "ArticleIdList": ["PMC7537250", "33105980"]}, {"Citation": "Reuken PA, W\u00fcst M, L\u00f6ffler B, Bauer M, Stallmach A. Letter: SARS-CoV-2-induced gastrointestinal inflammation. Aliment Pharmacol Ther. 2020;52:1748\u20131749.", "ArticleIdList": ["PMC7753794", "33205881"]}, {"Citation": "Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A. Review of inflammatory bowel disease and COVID-19. World J Gastroenterol. 2020;26:5534\u20135542.", "ArticleIdList": ["PMC7545397", "33088153"]}, {"Citation": "Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. Ageing Res Rev. 2020;62:101123.", "ArticleIdList": ["PMC7365123", "32683039"]}, {"Citation": "Kavaliers M, Innes DG. Novelty-induced opioid analgesia in deer mice (Peromyscus maniculatus): sex and population differences. Behav Neural Biol. 1988;49:54\u201360.", "ArticleIdList": ["3345191"]}, {"Citation": "Bhuiyan FR, Howlader S, Raihan T, Hasan M. Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. Front Med (Lausanne) 2020;7:444.", "ArticleIdList": ["PMC7427128", "32850918"]}, {"Citation": "Panyod S, Ho CT, Sheen LY. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. J Tradit Complement Med. 2020;10:420\u2013427.", "ArticleIdList": ["PMC7260602", "32691006"]}, {"Citation": "Huang J, Tao G, Liu J, Cai J, Huang Z, Chen JX. Current Prevention of COVID-19: Natural Products and Herbal Medicine. Front Pharmacol. 2020;11:588508.", "ArticleIdList": ["PMC7597394", "33178026"]}, {"Citation": "Boozari M, Hosseinzadeh H. Natural products for COVID\u201019 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res 2020.", "ArticleIdList": ["32985017"]}, {"Citation": "Naik B, Gupta N, Ojha R, Singh S, Prajapati VK, Prusty D. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Int J Biol Macromol. 2020;160:1\u201317.", "ArticleIdList": ["PMC7250083", "32470577"]}, {"Citation": "da Silva Antonio A, Wiedemann LSM, Veiga-Junior VF. Natural products' role against COVID-19. RSC Adv 2020; 10: 23379-23393.", "ArticleIdList": ["PMC9122563", "35693131"]}, {"Citation": "Chen H, Du Q. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection. 2020 Preprint. Available from: 202001.0358.v3."}, {"Citation": "Seadawy MG, Gad AF, Shamel M, Elharty B, Mohamed MF, Elfiky AA, Ahmed A, Zekri ARN. in vitro: Natural Compounds (Thymol, Carvacrol, Hesperidine, And Thymoquinone) Against SARS-CoV2 Strain Isolated From Egyptian Patients. 2020 Preprint. Available from: 2020.11.07.367649."}, {"Citation": "Muchtaridi M, Fauzi M, Khairul Ikram NK, Mohd Gazzali A, Wahab HA. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules. 2020;25", "ArticleIdList": ["PMC7504743", "32882868"]}, {"Citation": "Dabaghian F, Khanavi M, Zarshenas MM. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19. Med Hypotheses. 2020;143:109841.", "ArticleIdList": ["PMC7229719", "32425303"]}, {"Citation": "Kulkarni SA, Nagarajan SK, Ramesh V, Palaniyandi V, Selvam SP, Madhavan T. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. J Mol Struct. 2020;1221:128823.", "ArticleIdList": ["PMC7334662", "32834111"]}, {"Citation": "Rathinavel T, Meganathan B, Kumarasamy S, Ammashi S, Thangaswamy S, Ragunathan Y, Palanisamy S. Potential COVID-19 Drug from Natural Phenolic Compounds through In Silico Virtual Screening Approach. Biointerface Res Appl Chem 2020; 10161-10173."}, {"Citation": "Solnier J, Fladerer JP. Flavonoids: A complementary approach to conventional therapy of COVID-19? Phytochem Rev 2020; 1-23.", "ArticleIdList": ["PMC7500502", "32982616"]}, {"Citation": "Luo P, Liu D, Li J. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents. 2020;55:105995.", "ArticleIdList": ["PMC7180159", "32335281"]}, {"Citation": "Dowluru KS, Rao KRS. Phylogenetic analysis and In silico Screening of drug targets for ACE2 in Human and Spike Glycoprotein in Sars-CoV-2 for control of COVID19. 2020 Preprint. Available from: rs.3.rs-23862/v1."}, {"Citation": "Mhatre S, Naik S, Patravale V. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2. Comput Biol Med. 2021;129:104137.", "ArticleIdList": ["PMC7682485", "33302163"]}, {"Citation": "Jang M, Park R, Park YI, Cha YE, Yamamoto A, Lee JI, Park J. EGCG, a green tea polyphenol, inhibits human coronavirus replication in\u00a0vitro. Biochem Biophys Res Commun. 2021;547:23\u201328.", "ArticleIdList": ["PMC7874949", "33588235"]}, {"Citation": "Lichtenstein GR, Rubin DT. Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. Am J Gastroenterol. 2020;115:1566\u20131569.", "ArticleIdList": ["PMC7499877", "32833732"]}, {"Citation": "Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021;27:155\u2013161.", "ArticleIdList": ["PMC7665507", "33089863"]}, {"Citation": "Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271\u2013281.", "ArticleIdList": ["PMC7906670", "33545083"]}, {"Citation": "Zingone F, Buda A, Savarino EV. Starting a biologic therapy in IBD patients amidst COVID-19: hold, careful monitoring or testing? J Crohns Colitis. 2020", "ArticleIdList": ["PMC7314087", "32426800"]}, {"Citation": "Attauabi M, Seidelin J, Burisch J Danish COVID-IBD Study Group. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut. 2021;70:2020\u20132022.", "ArticleIdList": ["33658323"]}, {"Citation": "Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55", "ArticleIdList": ["PMC7236828", "32341100"]}, {"Citation": "Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19) Obstet Gynecol. 2020;136:823\u2013826.", "ArticleIdList": ["32769659"]}, {"Citation": "Tlayjeh H, Mhish OH, Enani MA, Alruwaili A, Tleyjeh R, Thalib L, Hassett L, Arabi YM, Kashour T, Tleyjeh IM. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. J Infect Public Health 2020.", "ArticleIdList": ["PMC7522674", "33008778"]}, {"Citation": "Brenner EJ, Pigneur B, Focht G, Zhang X, Ungaro RC, Colombel JF, Turner D, Kappelman MD, Ruemmele FM. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clin Gastroenterol Hepatol. 2021;19:394\u2013396.e5.", "ArticleIdList": ["PMC7550063", "33059040"]}, {"Citation": "El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021;37:313\u2013319.", "ArticleIdList": ["PMC8285035", "33859104"]}, {"Citation": "Gutin LS, Lam AY, Velayos FS, Santos SA. Going Viral: Management of IBD in the Era of the COVID-19 Pandemic. Dig Dis Sci. 2020;65:1571\u20131575.", "ArticleIdList": ["PMC7196441", "32363528"]}, {"Citation": "Schuurmans MM, Hage R. Cyclosporine A and COVID-19 - The COQUIMA cohort. EClinicalMedicine. 2021;31:100680.", "ArticleIdList": ["PMC7772530", "33385129"]}, {"Citation": "Pathania YS. Cyclosporine: hope for severe COVID-19? BMJ Support Palliat Care 2021 .", "ArticleIdList": ["33455917"]}, {"Citation": "Al-Ani AH, Prentice RE, Christensen B. Letter to the Editor: Care of the Patient with IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis 2020.", "ArticleIdList": ["PMC7543324", "32929469"]}, {"Citation": "Ghoshal UC, Sahu S, Biswas SN, Singh P, Chaudhary M, Ghoshal U, Tiwari P, Rai S, Mishra SK. Care of inflammatory bowel disease patients during coronavirus disease\u201019 pandemic using digital health\u2010care technology. JGH Open 2021.", "ArticleIdList": ["PMC8013680", "33821221"]}, {"Citation": "Mansouri P, Farshi S, Nickhah N, Nobari NN, Chalangari R, Nilforoushzadeh MA. Immunosuppressive/Immunomodulatory Therapies in Dermatology and COVID-19. Clin Dermatol 2021.", "ArticleIdList": ["PMC7884222", "34518013"]}, {"Citation": "D\u2019Silva KM, Serling-Boyd N, Hsu TY, Sparks JA, Wallace ZS. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Ann Rheum Dis 2021.", "ArticleIdList": ["PMC8482283", "33436385"]}, {"Citation": "Kasperkiewicz M. COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases. J Am Acad Dermatol. 2021;84:563\u2013568.", "ArticleIdList": ["PMC7414356", "32781181"]}, {"Citation": "Festa S, Aratari A, De Biasio F, Fasc\u00ec-Spurio F, Papi C. Screening for active COVID-19 infection prior to biologic therapy in IBD patients: Let's not increase our uncertainty without reducing our concerns. Dig Liver Dis 2020; 52: 1246-1247.", "ArticleIdList": ["PMC7247967", "32527654"]}, {"Citation": "Danese S, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020;17:253\u2013255.", "ArticleIdList": ["PMC7095422", "32214232"]}, {"Citation": "Weissman S, Aziz M, Smith WL, Elias S, Swaminath A, Feuerstein JD. Safety of biologics in inflammatory bowel disease patients with COVID-19. Int J Colorectal Dis. 2021;36:2051\u20132055.", "ArticleIdList": ["PMC8205311", "34131784"]}, {"Citation": "Gargallo-Puyuelo CJ, Laredo V, Gomoll\u00f3n F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907.", "ArticleIdList": ["PMC8322650", "34336887"]}, {"Citation": "Aysha AA, Rentsch C, Prentice R, Johnson D, Bryant RV, Ward MG, Costello SP, Lewindon P, Ghaly S, Connor SJ, Begun J, Christensen B. Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Intern Med J. 2020;50:798\u2013804.", "ArticleIdList": ["PMC7405147", "32656985"]}, {"Citation": "Weidinger C, Hegazy AN, Glauben R, Siegmund B. COVID-19\u2014from mucosal immunology to IBD patients. Mucosal Immunol 2021; 1-8.", "ArticleIdList": ["PMC7893623", "33608656"]}, {"Citation": "Shields S, Dunlop A, Seenan JP, Macdonald J. Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic. BMJ 2020.", "ArticleIdList": ["PMC8231430", "34249322"]}, {"Citation": "Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72:340\u2013350.", "ArticleIdList": ["PMC7337668", "33501974"]}, {"Citation": "Norsa L, Indriolo A, Sansotta N, Cosimo P, Greco S, D'Antiga L. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology 2020; 159: 371-372.", "ArticleIdList": ["PMC7270273", "32247695"]}, {"Citation": "Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut. 2020;69:1148\u20131149.", "ArticleIdList": ["32245909"]}, {"Citation": "Tursi A, Papa A. Impact of Anti-TNF\u03b1 Antibodies on the Risk of Covid-19 and its Severity in Patients with Inflammatory Bowel Diseases. J Crohns Colitis. 2020;14:1646\u20131647.", "ArticleIdList": ["PMC7188162", "32303756"]}, {"Citation": "Bodini G, Demarzo MG, Casagrande E, De Maria C, Kayali S, Ziola S, Giannini EG. Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management. Eur J Clin Invest. 2020;50:e13233.", "ArticleIdList": ["PMC7235524", "32294238"]}, {"Citation": "Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, Papa A. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut 2020; 69: 1364-1365.", "ArticleIdList": ["32312788"]}, {"Citation": "Allocca M, Fiorino G, Furfaro F, Gilardi D, Radice S, D'Amico F, Zilli A, Danese S. Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2020;18:1882\u20131883.", "ArticleIdList": ["PMC7158816", "32304737"]}, {"Citation": "Jacobs J, Clark-Snustad K, Lee S. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib. Inflamm Bowel Dis. 2020;26:e64.", "ArticleIdList": ["PMC7197538", "32342098"]}, {"Citation": "Taxonera C, Sagastagoitia I, Alba C, Ma\u00f1as N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276\u2013283.", "ArticleIdList": ["PMC7267496", "32359205"]}, {"Citation": "Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020;18:2134\u20132135.", "ArticleIdList": ["PMC7191273", "32360811"]}, {"Citation": "Mak JWY, Weng MT, Wei SC, Ng SC. Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. J Gastroenterol Hepatol. 2021;36:171\u2013173.", "ArticleIdList": ["PMC7361268", "32589798"]}, {"Citation": "Bardasi G, Alvisi P. SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor \u03b1 therapy? Dig Liver Dis. 2020;52:1244\u20131245.", "ArticleIdList": ["PMC7831628", "32703727"]}, {"Citation": "Ashton JJ, Kammermeier J, Spray C, Russell RK, Hansen R, Howarth LJ, Torrente F, Deb P, Renji E, Muhammed R, Paul T, Kiparissi F, Epstein J, Lawson M, Hope B, Zamvar V, Narula P, Kadir A, Devadason D, Bhavsar H, Beattie RM. Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study. Arch Dis Child. 2020;105:1186\u20131191.", "ArticleIdList": ["32732316"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "3", "Day": "16"}, {"Year": "2021", "Month": "5", "Day": "12"}, {"Year": "2021", "Month": "11", "Day": "28"}, {"Year": "2022", "Month": "1", "Day": "20", "Hour": "5", "Minute": "58"}, {"Year": "2022", "Month": "1", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "14"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35046622", "PMC8678820", "10.3748/wjg.v27.i46.7943"]}}], "PubmedBookArticle": []}